Introduction
This appendix catalogs FDA-cleared/approved AI tools and widely-used decision support systems organized by medical specialty. Information current as of 2024. Note: FDA clearance does not guarantee clinical effectiveness—physicians should review validation evidence before adoption.
Legend: - FDA Status: 510(k) = cleared, PMA = approved, De Novo = novel device clearance - Evidence Level: RCT = randomized controlled trial, Prospective = prospective cohort, Retrospective = retrospective validation only
Radiology
Chest X-Ray
| Annalise CXR | 
Annalise.ai | 
510(k) | 
Multi-finding detection (124 findings) | 
Retrospective | 
Comprehensive abnormality detection | 
| ClearRead CT | 
Riverain Technologies | 
510(k) | 
Lung nodule detection | 
Prospective | 
Bone suppression technology | 
| Lunit INSIGHT CXR | 
Lunit | 
510(k) | 
Pneumothorax, nodule, effusion detection | 
Prospective | 
High sensitivity (>95%) for PTX | 
| qXR | 
Qure.ai | 
510(k) | 
TB, COVID-19, nodule detection | 
Prospective | 
Validated in low-resource settings | 
| RedDot | 
Behold.ai | 
510(k) | 
Triage abnormal CXRs | 
Retrospective | 
Prioritizes urgent findings | 
Chest CT
| Aidoc Pulmonary Embolism | 
Aidoc | 
510(k) | 
PE detection, triage | 
Prospective | 
Integrated with PACS, mobile alerts | 
| Arterys Pulmonary Workstation | 
Arterys | 
510(k) | 
Lung nodule quantification | 
Retrospective | 
FDA first cloud-based AI (2017) | 
| Lung AI | 
Thirona | 
510(k) | 
Emphysema quantification | 
Prospective | 
COPD assessment | 
| AVIEW LCS | 
Coreline Soft | 
510(k) | 
Lung cancer screening, nodule management | 
Retrospective | 
Lung-RADS integration | 
| Veolity | 
MeVis | 
510(k) | 
Automated lung nodule volumetry | 
Prospective | 
Tumor tracking, treatment response | 
Head CT
| Aidoc ICH | 
Aidoc | 
510(k) | 
Intracranial hemorrhage detection | 
Prospective | 
Flags all hemorrhage types | 
| Brainomix e-ASPECTS | 
Brainomix | 
510(k) | 
Stroke ASPECTS scoring | 
Prospective | 
Quantifies early ischemic changes | 
| RapidAI | 
iSchemaView | 
510(k) | 
LVO detection, perfusion analysis | 
RCT | 
Reduces time-to-treatment | 
| Viz.ai LVO | 
Viz.ai | 
510(k) | 
LVO stroke triage | 
RCT (ENDOVASCT-trial) | 
Mobile team notification | 
| Avicenna cHeadCT | 
Avicenna.AI | 
510(k) | 
Multi-pathology triage (ICH, fracture, mass) | 
Prospective | 
Comprehensive head CT analysis | 
Mammography
| Transpara | 
ScreenPoint Medical | 
510(k) | 
Breast cancer detection | 
RCT | 
Improves detection, reduces false positives | 
| Genius AI | 
Hologic | 
510(k) | 
CAD for tomosynthesis | 
Prospective | 
Integrated with Hologic DBT | 
| ProFound AI | 
iCAD | 
510(k) | 
Breast cancer detection | 
Retrospective | 
Deep learning CAD | 
| Mia (Second Reader) | 
Kheiron Medical | 
CE Mark (EU) | 
Breast cancer detection | 
RCT (Sweden) | 
Supports single-reader workflow | 
| Volpara | 
Volpara Health | 
510(k) | 
Breast density assessment | 
Prospective | 
Automated BI-RADS density classification | 
Cardiac Imaging
| Arterys Cardio AI | 
Arterys | 
510(k) | 
Cardiac MRI quantification (EF, volumes) | 
Retrospective | 
Automated ventricular assessment | 
| Circle CVI | 
Circle Cardiovascular Imaging | 
510(k) | 
Cardiac MRI/CT post-processing | 
Prospective | 
FDA-cleared suite | 
| ClearRead + Bone Suppression | 
Riverain | 
510(k) | 
Rib suppression for cardiac imaging | 
Retrospective | 
Improves cardiac silhouette evaluation | 
| CT FFR | 
HeartFlow | 
PMA | 
Fractional flow reserve from CT | 
RCT (PLATFORM) | 
Non-invasive coronary physiology | 
Ophthalmology
| IDx-DR | 
Digital Diagnostics | 
De Novo | 
Diabetic retinopathy screening | 
RCT | 
First autonomous AI diagnostic (2018) | 
| EyeArt | 
Eyenuk | 
510(k) | 
Diabetic retinopathy detection | 
Prospective | 
Point-of-care screening | 
| RETFound | 
Multiple vendors | 
Research | 
Foundation model for retinal disease | 
Retrospective | 
Emerging technology | 
| LumineticsCore | 
Visulytix | 
510(k) | 
AMD progression risk | 
Retrospective | 
Predicts geographic atrophy growth | 
| Altris AI AMD | 
Altris AI | 
510(k) | 
AMD detection and monitoring | 
Retrospective | 
OCT analysis | 
Dermatology
| DermAssist | 
Google | 
Research | 
Skin condition identification | 
Retrospective | 
Not yet FDA-cleared | 
| SkinVision | 
SkinVision | 
CE Mark (EU) | 
Melanoma risk assessment | 
Retrospective | 
Smartphone app | 
| MoleScope | 
MetaOptima | 
510(k) (device only) | 
Dermoscopy imaging | 
N/A | 
Device cleared, AI pending | 
| VisualDx | 
VisualDx | 
N/A (CDSS) | 
Diagnostic decision support | 
N/A | 
Image database, not AI diagnostic | 
Note: Dermatology AI regulatory pathway still evolving. Many tools in development.
Cardiology
ECG Analysis
| Apple Watch ECG | 
Apple | 
510(k) | 
Atrial fibrillation detection | 
Prospective (Apple Heart Study) | 
Consumer wearable | 
| KardiaMobile | 
AliveCor | 
510(k) | 
AFib, bradycardia, tachycardia detection | 
Prospective | 
Smartphone-based ECG | 
| Cardiologs | 
Cardiologs | 
510(k) | 
Multi-arrhythmia detection | 
Retrospective | 
Cloud-based ECG interpretation | 
| Eko AI | 
Eko Health | 
510(k) | 
AFib detection from digital stethoscope | 
Prospective | 
Point-of-care screening | 
Echocardiography
| Caption Guidance | 
Caption Health | 
510(k) | 
AI-guided echo acquisition | 
Prospective | 
Helps non-experts capture images | 
| Us2.ai | 
Us2.ai | 
CE Mark (EU) | 
Automated ejection fraction | 
Retrospective | 
Point-of-care EF assessment | 
| TTE.ai | 
Bay Labs | 
510(k) | 
Automated EF, view classification | 
Retrospective | 
Workflow efficiency tool | 
Pathology
| Paige Prostate | 
Paige | 
510(k) | 
Prostate cancer detection | 
Retrospective | 
First FDA-cleared digital pathology AI | 
| PathAI | 
PathAI | 
Research | 
Multi-organ pathology analysis | 
Retrospective | 
Partnership with pharma for trials | 
| Prosigna | 
Veracyte | 
PMA | 
Breast cancer gene signature | 
RCT | 
Predicts recurrence risk | 
| Ibex Galen | 
Ibex | 
CE Mark (EU) | 
Breast, prostate cancer detection | 
Retrospective | 
Whole slide image analysis | 
Neurology
| Viz.ai LVO | 
Viz.ai | 
510(k) | 
Stroke detection (see Radiology) | 
RCT | 
Cross-specialty tool | 
| RapidAI | 
iSchemaView | 
510(k) | 
Stroke imaging analysis | 
RCT | 
Perfusion, ASPECTS, LVO | 
| Brainomix e-Stroke | 
Brainomix | 
510(k) | 
Stroke workflow suite | 
Prospective | 
Combines multiple analyses | 
| Icometrix | 
icobrain | 
CE Mark (EU) | 
MS lesion quantification | 
Prospective | 
Brain volumetrics | 
| Cortechs.ai | 
Cortechs Labs | 
510(k) | 
Brain MRI volumetrics | 
Retrospective | 
Neurodegenerative disease tracking | 
Primary Care / Internal Medicine
| Epic Sepsis Model | 
Epic Systems | 
N/A (EHR-embedded) | 
Sepsis risk prediction | 
Retrospective (poor external validation) | 
See Case Studies appendix—controversial | 
| Ambient Clinical Documentation | 
Multiple (Nuance DAX, Abridge, Suki) | 
N/A (non-diagnostic) | 
AI-generated clinical notes | 
Prospective | 
Reduces documentation burden | 
| UpToDate with AI | 
Wolters Kluwer | 
N/A (CDSS) | 
Clinical decision support | 
N/A | 
Evidence summaries, not AI diagnostic | 
Gastroenterology
| GI Genius | 
Medtronic | 
510(k) | 
Colonoscopy polyp detection | 
RCT | 
Real-time CAD during procedure | 
| EndoBRAIN | 
Olympus/Cybernet | 
Research (Japan approval) | 
Polyp characterization | 
Prospective | 
Predicts histology in real-time | 
| CAD EYE | 
Fujifilm | 
CE Mark (EU) | 
Polyp detection during colonoscopy | 
Prospective | 
Integrated with endoscope | 
Oncology
| Oncotype DX | 
Exact Sciences | 
PMA (not AI, genomic test) | 
Breast cancer recurrence risk | 
RCT | 
Guides chemotherapy decisions | 
| Tempus | 
Tempus Labs | 
N/A (genomic analysis) | 
Precision oncology | 
Retrospective | 
AI-powered genomic matching to trials | 
| Foundation Medicine | 
Roche | 
PMA | 
Comprehensive genomic profiling | 
Retrospective | 
Identifies actionable mutations | 
| Paige Prostate | 
Paige | 
510(k) (see Pathology) | 
Prostate cancer detection | 
Retrospective | 
Digital pathology AI | 
Anesthesiology / Critical Care
| Masimo sedation monitoring | 
Masimo | 
510(k) | 
Depth of sedation assessment | 
Prospective | 
Non-AI advanced monitoring | 
| Edwards HPI | 
Edwards Lifesciences | 
510(k) | 
Hypotension prediction | 
Prospective | 
Predicts hypotension 15 min advance | 
| ICU EarlyWarning Systems | 
Multiple vendors | 
Variable | 
Sepsis, deterioration prediction | 
Mixed | 
Many still experimental | 
Pulmonology
| Qure.ai qXR | 
Qure.ai | 
510(k) | 
TB detection on CXR | 
Prospective | 
Validated in endemic regions | 
| CAD4TB | 
Delft Imaging | 
CE Mark (EU) | 
TB screening | 
Prospective | 
WHO-endorsed for resource-limited settings | 
| Lung Texture Analysis | 
VIDA Diagnostics | 
510(k) | 
COPD, ILD quantification | 
Prospective | 
CT-based lung parenchyma analysis | 
Mental Health / Psychiatry
| Woebot | 
Woebot Health | 
N/A (wellness, not diagnostic) | 
CBT chatbot | 
Prospective | 
Mental health support app | 
| Ginger | 
Ginger (Headspace Health) | 
N/A | 
Behavioral health coaching | 
Retrospective | 
AI triage + human coaches | 
| Mindstrong | 
Mindstrong Health | 
Research | 
Smartphone keystroke patterns predict mood | 
Retrospective | 
Experimental, not yet FDA-cleared | 
Note: AI in psychiatry highly sensitive—regulatory scrutiny intense, adoption slow.
Obstetrics / Maternal-Fetal Medicine
| Sonio AI | 
Sonio | 
CE Mark (EU) | 
Ultrasound guidance, anomaly detection | 
Retrospective | 
Assists sonographers | 
| Prenatal AI | 
Multiple vendors | 
Research | 
Fetal anomaly detection | 
Retrospective | 
Emerging field, limited deployment | 
Emergency Medicine
Many emergency AI tools cross specialties (e.g., head CT hemorrhage detection, CXR pneumothorax). See Radiology section for trauma/emergency imaging AI.
| Viz.ai | 
Viz.ai | 
510(k) | 
Stroke, PE, aneurysm triage | 
RCT | 
Multi-pathology platform | 
| Aidoc | 
Aidoc | 
510(k) | 
Multi-pathology ED triage | 
Prospective | 
ICH, PE, c-spine fracture, etc. | 
Urology
| Arterys Prostate MRI | 
Arterys | 
510(k) | 
Prostate MRI PI-RADS scoring | 
Retrospective | 
Automated lesion detection | 
| Watson for Genomics | 
IBM (discontinued) | 
N/A | 
Precision oncology for urologic cancers | 
Retrospective | 
See IBM Watson case study—failed | 
Limitations and Caveats
1. FDA clearance ≠ effectiveness: Clearance means device is “substantially equivalent” to predicate (510k) or meets safety/efficacy standards (PMA). Does not guarantee clinical benefit in all settings.
2. Evidence quality varies: Many tools have only retrospective validation. Prospective, multi-site RCTs are gold standard but rare.
3. Continuous updates: AI tools evolve. This catalog reflects 2024 status—check FDA database and vendor websites for updates.
4. Reimbursement often absent: Few AI tools have dedicated CPT codes. Check with payers before assuming coverage.
5. Integration challenges: FDA-cleared tool may not integrate with your EHR, PACS, or workflow without significant IT effort.
6. Performance varies by population: Models trained on one population may underperform in yours. Validate locally before widespread use.
7. Vendor claims vs. reality: Marketing often overstates capabilities. Demand peer-reviewed publications, not just vendor white papers.
Conclusion
This catalog provides starting point for exploring specialty-specific AI tools. The field evolves rapidly—new tools emerge, existing tools improve or fail. Physicians must stay informed, demand evidence, and critically evaluate AI claims before adoption.
For updated FDA clearances, visit: https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-and-machine-learning-aiml-enabled-medical-devices
Remember: AI is tool, not replacement. Physician judgment, contextual understanding, and patient relationships remain irreplaceable.